


α -Glucosidase-IN-11

Cat. No.:	HY-150560
CAS No.:	2411744-76-6
Molecular Formula:	C ₂₃ H ₂₀ N ₂ O ₆
Molecular Weight:	420.41
Target:	Glucosidase
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	α -Glucosidase-IN-11 is a highly permeable competitive α -glucosidase inhibitor with the IC ₅₀ value of 0.56 μ M. α -Glucosidase-IN-11 binds to Trp residues in α -glucosidase and regulates protein folding. α -Glucosidase-IN-11 can be used to regulate blood glucose levels ^[1] .								
In Vitro	<p>α-Glucosidase-IN-11 (compound 3k) inhibits α-glucosidase, α-fucosidase and α-mannosidase with the IC₅₀ value of 0.56 μM, 30.4 μM and 41.2 μM, respectively^[1].</p> <p>α-Glucosidase-IN-11 (compound 3k) (0.1-100 μM, 24 hours) can induce β-cell proliferation at lower concentration^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Proliferation Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>BRIN-BD11 cells (rat beta cell line)</td> </tr> <tr> <td>Concentration:</td> <td>0.1-100 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 hours</td> </tr> <tr> <td>Result:</td> <td>Showed cell proliferation at low concentration of 1 μM and minor cytotoxic effect at higher concentration greater than 10 μM.</td> </tr> </table>	Cell Line:	BRIN-BD11 cells (rat beta cell line)	Concentration:	0.1-100 μ M	Incubation Time:	24 hours	Result:	Showed cell proliferation at low concentration of 1 μ M and minor cytotoxic effect at higher concentration greater than 10 μ M.
Cell Line:	BRIN-BD11 cells (rat beta cell line)								
Concentration:	0.1-100 μ M								
Incubation Time:	24 hours								
Result:	Showed cell proliferation at low concentration of 1 μ M and minor cytotoxic effect at higher concentration greater than 10 μ M.								
In Vivo	<p>α-Glucosidase-IN-11 (compound 3k) (gastric gavage, 60 mg/kg, everyday, 4 weeks) can improve blood glucose levels during fasting^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Male Sprague Dawley rats (250e320g)^[1]</td> </tr> <tr> <td>Dosage:</td> <td>60 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Gastric gavage; everyday; 4 weeks</td> </tr> <tr> <td>Result:</td> <td>Caused a significant drop in fasting blood glucose during the first and second weeks but did not cause a decrease in non-fasting blood glucose for up to four weeks.</td> </tr> </table>	Animal Model:	Male Sprague Dawley rats (250e320g) ^[1]	Dosage:	60 mg/kg	Administration:	Gastric gavage; everyday; 4 weeks	Result:	Caused a significant drop in fasting blood glucose during the first and second weeks but did not cause a decrease in non-fasting blood glucose for up to four weeks.
Animal Model:	Male Sprague Dawley rats (250e320g) ^[1]								
Dosage:	60 mg/kg								
Administration:	Gastric gavage; everyday; 4 weeks								
Result:	Caused a significant drop in fasting blood glucose during the first and second weeks but did not cause a decrease in non-fasting blood glucose for up to four weeks.								

REFERENCES

[1]. Tania Luthra, et al. Discovery of novel pyrido-pyrrolidine hybrid compounds as alpha-glucosidase inhibitors and alternative agent for control of type 1 diabetes. Eur J Med Chem. 2020 Feb 15;188:112034.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA